Showing results (381-390 of 392) with videos related to

Sort By:
Pageof 40
Gynecologic Oncology|January 29, 2019
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancerRachel M Hurley, Andrea E Wahner Hendrickson, Daniel W Visscher, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 15, 2020
Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancerE J van Helden, S G Elias, S L Gerritse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2025
Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker AnalysesStefan G van Ravensteijn, Jacco J de Haan, Hans Gelderblom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2012
Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumorsC C E Koning, L E C M Blank, C Koedooder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery ProtocolBirgit S Geurts, Laurien J Zeverijn, Lindsay V M Leek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2022
[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell CarcinomaSarah R Verhoeff, Sjoukje F Oosting, Sjoerd G Elias, et al.
Diagnostics (Basel, Switzerland)|February 24, 2024
Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast CancerJorianne Boers, Bertha Eisses, Mieke C Zwager, et al.
Nature|October 2, 2019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsD L van der Velden, L R Hoes, H van der Wijngaart, et al.
International Journal of Cancer|July 10, 2023
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trialsLaurien J Zeverijn, Eleonora J Looze, Subotheni Thavaneswaran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery ProtocolLaurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia, et al.
Pageof 40